Replimune Group (REPL)
(Real Time Quote from BATS)
$11.04 USD
+0.58 (5.55%)
Updated Sep 17, 2024 03:55 PM ET
After-Market: $11.03 -0.01 (-0.09%) 4:12 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 1 - 20 ( 201 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Tracking to Commercialization; Initiating at Buy and $17 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Oncolytic Immunotherapy -Initiating coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
We Think IGNYTE Top-Line Primary Data Support BLA Filing; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
IGNYTE-3 in Q3; Central Review Consistent with Investigator Assessment
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
BLA Submission For RP1 Expected in 2H24; F3Q24 Results Reported; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q3 Financials; IGNYTE BLA and Confirmatory Trial for 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 + Libtayo Whiffs on CERPASS Endpoints; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Quality, but Just Missing on Quantity; IGNYTE Supports BLA Filing Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Updated ARTACUS Data; F2Q24 Results; Lowering PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Fiscal Financials; Key Early December Update Planned
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
F1Q24 Financial Results Reported; Modulating PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R